Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables (2018 - 2025)

Historic Receivables for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $1.4 million.

  • China SXT Pharmaceuticals' Receivables fell 1217.37% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 1217.37%. This contributed to the annual value of $3.8 million for FY2025, which is 2145.12% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Receivables stood at $1.4 million for Q3 2025, which was down 1217.37% from $1.7 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Receivables registered a high of $6.9 million during Q3 2021, and its lowest value of $1.3 million during Q3 2023.
  • Over the past 5 years, China SXT Pharmaceuticals' median Receivables value was $3.1 million (recorded in 2023), while the average stood at $3.5 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 7840.71% in 2023, then skyrocketed by 1776.28% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Receivables (Quarter) stood at $6.9 million in 2021, then decreased by 11.51% to $6.1 million in 2022, then plummeted by 78.41% to $1.3 million in 2023, then increased by 17.76% to $1.5 million in 2024, then dropped by 12.17% to $1.4 million in 2025.
  • Its Receivables was $1.4 million in Q3 2025, compared to $1.7 million in Q1 2025 and $1.5 million in Q3 2024.